Linvoseltamab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | CD3 and BCMA |
| Clinical data | |
| Trade names | Lynozyfic |
| Other names | REGN5458, REGN-5458, linvoseltamab-gcpt |
| License data | |
| Routes of administration | Intravenous |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6455H9955N1721O2039S47 |
| Molar mass | 145800.47 g·mol−1 |
Linvoseltamab, sold under the brand name Lynozyfic, is an anti-cancer medication used for the treatment of people with relapsed and refractory multiple myeloma. Linvoseltamab is a bispecific monoclonal antibody that targets CD3 and B-cell maturation antigen (BCMA) (TNFRSF17). It is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager and a recombinant human immunoglobulin (Ig)G4 antibody.
Lynozyfic was authorized for medical use in the European Union in April 2025, and approved for medical use in the United States in July 2025.